Divi's Laboratories Limited
Quick Take
- • Trading at 85.2× trailing earnings (62.3× forward)
- • Strong ROE at 17.5%
- • Low leverage (D/E 0.00)
- • Modest dividend yield of 0.32%
- • Operating margin 36.7% · Net margin 26.0%
- • Profit growth +65.70% YoY · Beta 0.24
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 3,080 | +8.80% | +19.15% |
| Operating Profit | 1,319 | +21.12% | +35.70% |
| Net Profit | 902 | +20.11% | +36.25% |
| EPS (₹) | 33.95 | +19.92% | +36.18% |
About the company
From latest AR & concallDivi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
